A retrospective review of rasburicase utilization in pediatric and adult patients across a large health system

Abstract

Purpose

This study aimed to characterize rasburicase dosing and duration. Secondary objectives included characterizing the indication of rasburicase and identifying the utilization of prophylactic therapy for tumor lysis syndrome (TLS).

Methods

This retrospective review included patients 0 to 89 years old admitted between 1 January 2021 and 31 December 2021, and received at least one dose of rasburicase. Patients were excluded if they were >89 years old, pregnant, lactating, or received rasburicase outpatient.

Results

A total of 192 patients, 176 adults and 16 pediatric patients were included in the retrospective review. Of the total population, 184 received a fixed dose of rasburicase and 8 patients received a weight-based dose (0.15 mg/kg/dose) of rasburicase. The average dose administered was 3.4 mg for fixed and 2.99 mg for weight-based dosing. Nearly half (49.5%) the patients received rasburicase for an elevated uric acid but did not meet Cairo-Bishop criteria for TLS. Only 42.2% received at least one dose of allopurinol within 5 days prior to rasburicase and 18.8% received aggressive hydration within 72 h prior to rasburicase.

Conclusion

The majority of rasburicase administered was ordered as fixed dose for a uric acid level ≥7.5 mg/dL. Most patients did not meet criteria for laboratory or clinical TLS and less than half the patients received prophylactic allopurinol and/or aggressive hydration. These study results are supported by recent literature for fixed dose rasburicase as a safe and economical dosing strategy compared to weight-based dosing.

Keywords

Rasburicase tumor lysis syndrome oncology weight-based dosing

Get full access to this article

View all access options for this article.

References

Rahmani

Patel

Seyam

, et al. Current understanding of tumor lysis syndrome. Hematol Oncol 2019; 37: 537–547.

Howard

, et al. The tumor lysis syndrome: Nejm. N Engl J Med 2011. https://www.nejm.org/doi/10.1056/NEJMra0904569. accessed 24 July 2022.

Coiffier

, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26: 2767–2778.

Gupta

Moore

. Tumor lysis syndrome. JAMA Oncol 2018; 4: 95.

National Comprehensive Cancer Network. B Cell Lymphomas (version 5.2022). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (2022, accessed 24 July 2022).

Matuszkiewicz-Rowinksa

Malyszko

. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res 2020; 45: 645–660.

Spina

, Nagy Z, Ribera JM, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 2015; 26: 2155–2161.

Vadhan-Raj

, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 2012; 23: 1640–1645.

, Liu L, Nie X, et al. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. J Clin Pharm Ther 2017; 42: 18–26.

10.

Coutsouvelis

, Wiseman M, Hui L, et al. Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol 2013; 75: 550–553.

11.

Trifilio

, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 2011; 46: 800–805.